$800M+ vaccine investment aims to boost pandemic readiness

HHS is investing more than $800 million in vaccine development and manufacturing capacity to strengthen the nation’s response capabilities to emerging infectious disease threats, including bird flu. 

Advertisement

Five notes: 

  • On Jan. 16, the agency said it intends to invest $211 million to support the development of an RNA-based vaccine technology platform and long-term manufacturing capabilities. The funds will be allocated through the agency’s Administration for Strategic Preparedness and Response.
  • “The funding will allow us to bring the benefits of mRNA vaccine technology to bear against a wider array of emerging threats,” Dawn O’Connell, assistant secretary for preparedness and response at HHS, said in a Jan. 16 news release. “mRNA technology can be faster to develop and easier to update than other vaccines making it a helpful tool to have against viruses that move fast and mutate quickly.”
  • HHS will also provide approximately $590 million to Moderna. The drugmaker will use the funds to accelerate development of pandemic influenza mRNA-based vaccines, according to a separate announcement Jan. 17.
  • The U.S. has announced a series of new measures aimed at accelerating the nation’s response to bird flu in recent days. On Jan. 14, the Biden administration released a 300-page playbook meant for future administrations to “protect the nation and effectively respond to any future biological threat.” On Jan. 16, the CDC published a health alert recommending hospitals perform subtyping to test for bird flu in all hospitalized patients who test positive for influenza A. 
  • The CDC has confirmed 67 cases of bird flu among humans since the spring of 2024. There has been no evidence of person-to-person transmission, and federal health officials maintain that the risk the disease poses to public health remains low.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Public Health

Advertisement

Comments are closed.